Ryan Maynard
Equibles does not estimate personal net worth.
Get an email with a short summary when Tvardi Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVRD alertsAbout Ryan Maynard
Ryan Maynard is recorded as CFO at Tvardi Therapeutics, Inc. (TVRD) since September 12, 2022. Tvardi Therapeutics, Inc. reported in an 8-K filed April 15, 2025 that Ryan Maynard was terminated as Chief Financial Officer, effective April 15, 2025. Tvardi Therapeutics, Inc. reported in an 8-K filed September 12, 2022 that Ryan Maynard was appointed Chief Financial Officer, effective September 12, 2022. The proxy statement of Tvardi Therapeutics, Inc. reports total compensation of $1,243,857 for Ryan Maynard in fiscal 2023, including a base salary of $478,400. Disclosed compensation is on record for 2 fiscal years. Tvardi Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tvardi Therapeutics, Inc. includes Derek Chalmers (CEO), Imran Alibhai (CEO and Board Member), Imran Alibhai, Ph.D. (CEO and Board Member) and 7 others.
“On April 15, 2025, effective upon the closing of the Merger, the employment of each of Christopher Posner, Ryan Maynard and Scott Terrillion as Cara's President and Chief Executive Officer, Cara's Chief Financial Officer, and Cara's General Counsel, Secretary and Chief Compliance Officer, respectively, was terminated.”
“On September 12, 2022, Cara Therapeutics, Inc. (the "Company") announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.”
Affiliation history
-
Current
2022-09-12–present
-
Start not stated–2025-04-15
Company network
Leadership on record at Tvardi Therapeutics, Inc.
- Derek Chalmers CEO
- Imran Alibhai CEO, Board Member
- Imran Alibhai, Ph.D. CEO, Board Member
- Sujal Shah Chairman, Board Member
- Dan Conn CFO
- Dan Conn, J.D., M.B.A CFO
- Dan Conn, J.D., M.B.A. CFO
- Mani Mohindru CFO
- Thomas Reilly CFO
- Scott M. Terrillion General Counsel
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Tvardi Therapeutics, Inc. (TVRD) | Chief Financial Officer | $478,400 | $1,243,857 |
| 2022 | Tvardi Therapeutics, Inc. (TVRD) | Chief Financial Officer | $140,600 | $1,889,302 |